Clinical trialNo phase (not a drug trial)Completed
Hair Loss Prevention Study for Pancreatic Cancer
A Hair Loss Prevention Study for Patients With Advanced Pancreatic Cancer Utilizing Scalp Cooling
- Outcome
- Results posted; single-arm, no comparison
- Phase
- No phase (not a drug trial)
- Status
- Completed
- Study type
- Interventional
- Start
- 13 December 2019
- Ended
- 31 December 2021
- Enrollment
- 9 participants
- Sites
- 1
- Primary outcomes
- Hair Preservation
- Sponsor type
- Academic / other
- Results posted
- 26 May 2026
- Last update
- 26 May 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 26 May 2026
- Primary outcome
- Hair PreservationGrade 1 alopecia: Paxman Scalp Cooling Device: 2 of 5Grade 2 alopecia: Paxman Scalp Cooling Device: 3 of 5Values: ParticipantsTime frame: 28 to 84 daysNo analysis posted for this outcome (outcome 1)
- Participants
- Paxman Scalp Cooling Device: 9 started, 9 completed
- Serious adverse events
- Paxman Scalp Cooling Device: 0 of 9Participants with at least one serious adverse event, of those at risk, as posted
2 secondary outcomes
- Patient Comfort
- very comfortable: Paxman Scalp Cooling Device 5/5 [Participants] (first of 5 rows)
- Chemotherapy-Induced Alopecia Distress
- Paxman Scalp Cooling Device 23 (8.08), n=7 [median score on a scale, Standard Deviation]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Pilot study intended for hair loss prevention in patients with pancreatic cancer who are receiving treatment containing nab-paclitaxel, gemcitabine and cisplatin.
Detailed description public domain (ClinicalTrials.gov)
Patients with pancreatic cancer who are receiving treatment containing nab-paclitaxel, gemcitabine and cisplatin will experience hair preservation with the use of the Paxman scalp cooling device, at the end of three, 3 week cycles of chemotherapy.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Hair Preservation [28 to 84 days]. Count Of Participants, Participants. Grade 1 alopecia: Paxman Scalp Cooling Device (n=5): 2. Grade 2 alopecia: Paxman Scalp Cooling Device (n=5): 3.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Patient Comfort [1 to 84 days]. Count Of Participants, Participants. very comfortable: Paxman Scalp Cooling Device (n=5): 5. reasonably comfortable: Paxman Scalp Cooling Device (n=5): 0. comfortable: Paxman Scalp Cooling Device (n=5): 0. uncomfortable: Paxman Scalp Cooling Device (n=5): 0. very uncomfortable: Paxman Scalp Cooling Device (n=5): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Chemotherapy-Induced Alopecia Distress [1 to 84 days]. Median, score on a scale (Standard Deviation). Paxman Scalp Cooling Device (n=7): 23 (8.08).